ABBV 319
Alternative Names: ABBV-319Latest Information Update: 14 Jun 2023
At a glance
- Originator AbbVie
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
Most Recent Events
- 26 Apr 2023 Phase-I clinical trials in Chronic lymphocytic leukaemia in USA (IV)
- 26 Apr 2023 Phase-I clinical trials in Diffuse large B cell lymphoma in USA (IV)
- 26 Apr 2023 Phase-I clinical trials in Follicular lymphoma in USA (IV)